tbuckley/cabot-search huggingface dataset:
Reviewer acknowledgment 2018
Authors: Otis W. Brawley, Ted Gansler
Journal: CA A Cancer Journal for Clinicians (2018)

The Editors of CA depend on the wisdom and advice of many experts in deciding which topics to pursue, which manuscripts to publish, and what modifications to make to ensure medical and scientific accuracy and suitability for our readers. We thank our Associate Editors and our Editorial Advisory Board, who have performed these services for us in the past year. We are also greatly indebted to the expertise, dedication, and expeditious response of the following individuals for reviewing at least one and, in some cases, many manuscripts for the journal from July 1, 2017, to June 30, 2018. Sylvia Asa Peter Boyle Graham Colditz Matthew Cooperberg Nessa Coyle Jennifer Croswell Sanjit Dadwal Mellar Davis Catherine Diefenbach John Epling Ruth Etzioni Stacey Fedewa Laura Finn Mayer Fishman Lewis Foxhall Gary Giovino Ilya Glezerman Thomas Glynn Leo I. Gordon Darrell Gray Carmen Guerra Seza Gulec Michael Hall Lauren Harshman Ernest Hawk Sarah Hawley Tara Henderson Jerome Hershman Eric Jacobs Whitney Jones Nandita Khera Simon P. Kim Carlo La Vecchia Bernard Levin Mary L. McBride Paul Nathan Ian Olver Judith Paice Alpa Patel Steven Pergam Daniel Reuland Jennifer Rosen Mark Sherman Carmen Solorzano Guru Sonpavde Dawn Stacey Stephen Taplin Ted Trimble Walter Willett Kerri Winters-Stone Xue Qin Yu
TCT-82 Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease: Insights From the EXCEL Trial
Authors: Carlos Collet, Gregg Stone, Nicholas Lembo, Adrian Banning, Martin Leon, Marie-Claude Morice, David Kandzari, Rod Stables, Yangbo Liu, Ovidiu Dressler, Joseph Sabik, A. Pieter Kappetein, Patrick Serruys
Journal: Journal of the American College of Cardiology (2017)
John (Seán) D Carroll
Authors: Áine Carroll
Journal: BMJ (2019)

John (Sean) D Carroll was born in Belfast. He was a medical student at the birth of the NHS and received the McGrath gold medal for medicine. A true public servant, he held true to the founding principles of the NHS throughout his career. As a medical student, he was impressed by the words of the professor of medicine, W W D Thompson, that doctors should practise on the basis of the following principles:

As a GP from 1957 to 1999, John laboured in the vineyard of Mourne …
CHARACTERISTICS OF HOSPITAL-ACQUIRED BLOODSTREAM INFECTIONS IN INTENSIVE CARE UNITS: THE EUROBACT STUDY
Authors: A. Tabah, D. Koulenti, S. Blot, B. Misset, F. Bruzzi de Carvalho, N. Cakar, A. Mikstacki, K. Laupland, J. Rello, C. Martin, J. R Zahar, J. F Timsit
Journal: Intensive Care Medicine (2011)
Attitude to electroconvulsive therapy is a sign of tribal affiliation
Authors: Vaughan Bell
Journal: BMJ (2019)

The fight about electroconvulsive therapy (ECT) shows how partisan divisions hold back progress in mental health.1 Rather than ECT being an intervention to be evaluated on evidence, the attitude towards it has become a sign of tribal affiliation.

The evidence for ECT is surprisingly poor compared with other treatments. There is no reliable evidence for long term benefits because …
AACR Cancer Progress Report 2016
Authors: Nancy E. Davidson, Scott A. Armstrong, Lisa M. Coussens, Marcia R. Cruz-Correa, Ralph J. DeBerardinis, James H. Doroshow, Margaret Foti, Patrick Hwu, Thomas W. Kensler, Monica Morrow, Charles G. Mulligan, William Pao, Elizabeth A. Platz, Thomas J. Smith, Cheryl L. Willman
Journal: Clinical Cancer Research (2016)

* This author contributed to the development and review of this manuscript but is unable to endorse the request for NIH funding .























It is a tremendously exciting time for the cancer community. Thanks to research, we are making significant progress against the many diseases we
改进实效型试验的报告质量：CONSORT声明的扩充（1）
Authors: Merrick, Zwarenstein, Shaun, Treweek, Joel, Gagnier, Douglas, Altman, Sean, Tunis, Brian, Haynes, Andrew, Oxman, David, Moher, 汪谋岳
Journal: BMJ (2009)

Objective
To review the clinical characteristics of left ventricular pseudo-aneurysm (LVPA) in China mainland.


Methods
The China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP information and PubMed database were searched to extract information on clinical profile, diagnostic imaging, treatment and outcome of patients with LVPA from January 1986 to April 2012.


Results
Clinical data of 77 patients with LVPAs (including 5 coexistent with true aneurysm) were extracted from 65 articles. There were 56 males (72.7%) and 11 females (27.3%) with a median age of 48 years old (range 5 to 82). The most common etiology was myocardial infarction (40, 51.9%). Breathlessness/dyspnea (44.6%), chest discomfort (41.9%) and chest pain (41.9%) were the most frequently reported symptoms, but asymptomatic patients accounted for 10.8% of all. 86.4% of the patients had electrocardiographic abnormalities, most of which were nonspecific ST segment changes. No event of thromboembolism was reported. Transthoracic echocardiography was the most commonly used diagnostic imaging test, followed by angiography with which no complication was reported. 19 cases of pseudo-aneurysms (24.7%) were reported to rupture and 15 patients(19.5%)died, mostly of cardiac tamponade and sudden death.


Conclusions
LVPA is a rare and life-threatening disorder. It lacks of specific clinical manifestations distinguishable from coronary disease or heart failure. Emergency surgery is warranted once it is identified.


Key words: 
Heart aneurysm; Heart ventricles; Retrospective studies
Is There an Alternative to Serotonin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT)? Evaluation of 5 Other Functional Methods Using 5B9 a Monoclonal IgG That Mimics HIT Human Antibodies
Authors: Eve-Anne Guéry, Caroline Vayne, Cloé Derray, Joévin Besombes, Wayne Corentin Lambert, Jérôme Rollin, Yves Gruel, Claire Pouplard
Journal: Blood (2018)
Characterization of chronic urticaria and associated conditions in a large population of adolescents
Authors: Yossi Rosman, Alon Y. Hershko, Keren Meir-Shafrir, Ron Kedem, Idit Lachover-Roth, Yoseph A. Mekori, Ronit Confino-Cohen
Journal: Journal of the American Academy of Dermatology (2019)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Authors: Fabien Picard, Deepak L. Bhatt, Grégory Ducrocq, Yedid Elbez, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Kim M. Fox, Philippe Gabriel Steg
Journal: Journal of the American College of Cardiology (2019)
Use of Electronic Vapor Products Before, During, and After Pregnancy Among Women with a Recent Live Birth — Oklahoma and Texas, 2015
Authors: Martha Kapaya, Denise V. D’Angelo, Van T. Tong, Lucinda England, Nan Ruffo, Shanna Cox, Lee Warner, Jennifer Bombard, Tanya Guthrie, Ayesha Lampkins, Brian A. King
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Electronic vapor products (EVPs) comprise a diverse group of devices, including electronic cigarettes (e-cigarettes). EVP users inhale an aerosol that typically contains nicotine, flavorings, and other additives (1). Nicotine is a developmental toxicant that adversely affects pregnancy and infant outcomes (2). Data from the 2015 Pregnancy Risk Assessment Monitoring System (PRAMS) for Oklahoma and Texas were analyzed to estimate population-based EVP use among women with a recent live birth. EVP use before pregnancy (defined as >3 months before pregnancy) and around the time of pregnancy (defined as any time during the 3 months before pregnancy, the last 3 months of pregnancy, or 2-6 months after delivery), reasons for EVP use, and dual use of EVPs and cigarettes were assessed. Prevalence of EVP use was 10.4% before pregnancy and 7.0% around the time of pregnancy, including 1.4% during the last 3 months of pregnancy. Among women using EVPs during the last 3 months of pregnancy, 38.4% reported use of EVPs containing nicotine, and 26.4% were unsure of nicotine content. Among women who had used EVPs and cigarettes, dual use prevalence was 38.0% in the 3 months before pregnancy, 7.7% during the last 3 months of pregnancy, and 11.8% in the 2-6 months after delivery. The most frequently reported reasons for EVP use around the time of pregnancy were curiosity (54.0%), the perception that EVPs might help with quitting or reducing cigarette smoking (45.2%), and the perception of reduced harm to the mother, when compared with cigarette smoking (45.2%). Clear messages that EVP use is not safe during pregnancy are needed, and broad, barrier-free access to evidence-based tobacco cessation strategies need to be made available.
The year in Gut 2008
Authors: Robin Spiller
Journal: Gut (2008)

As the year ends, we can look back at another great year for Gut . This is the year that our impact factor reached 10.0 (see figure) and we can say that Gut is now firmly established along with Gastroenterology and Hepatology as amongst the three top gastrointestinal journals in the world, covering the fields of gastroenterology and hepatology (see fig).





This has not been achieved without considerable effort and hard work from many people, including the Gut Editorial Office and the Associate Editors. Together, we are now processing manuscripts at a record speed. Our median time for first decision is just 11 days. Given that we only accept the very best, we must regrettably reject around 85% of all manuscripts, so it makes sense to make a quick decision without sending out for review those that obviously do not match the aims of Gut , which are shown on our website. These are “to publish original articles describing novel mechanisms of disease and new management strategies, both …
Identification of three tyrosine residues of importance for survival signaling of Flt3 ITD through Gab2
Authors: Kristina Masson, Tao Liu, Jianmin Sun, Lars Ronnstrand
Journal: Cancer Research (2008)

3472  The receptor tyrosine kinase Flt3 is normally expressed in hematopoietic progenitor cells and has been implicated as major cause of transformation in acute myeloid leukemia, where it in approximately 30 % of cases is constitutively active. Intracellular signals mediated by Flt3 play pivotal roles in cell fate determination and survival and previous studies have shown that signaling via the mutant Flt3 ITD (internal tandem duplication) promotes enhanced cell growth as compared to the wild type receptor. In this study, we have identified tyrosines 768, 955 and 969 of Flt3 as phosphorylation sites and mediators of Grb2 interaction, leading to the association of Gab2 and contributing to proliferation and survival. We used murine hematopoietic Ba/F3 cells stably transfected with either the wild type Flt3 or the ITD, with or without a triple mutation of the Grb2 binding sites, and have characterized the cells in terms of proliferation, survival and apoptosis. Interestingly, we found that the Flt3 ITD promotes increased survival and when mutating the tyrosines 768, 955 and 969 to phenylalanine, this phenotype is lost. When looking into different downstream pathways, we observed that this effect is mainly caused by decreased PI3-kinase/Akt as well as STAT5 signaling, and the Flt3 ITD carrying the triple mutation of the Grb2 binding sites show less Akt and STAT5 activation as compared to the regular Flt3 ITD receptor. These findings not only reveal new phosphorylation sites in Flt3 but contribute to the understanding of the molecular mechanism by which Flt3 ITD functions in pathological conditions.
ATM loss in NSCLC increases sensitivity to cisplatin and PARP inhibition
Authors: D.G. Bebb, L.F. Petersen, J. Moore, A. Elegbede, S. Lees-Miller
Journal: Annals of Oncology (2019)

Background: Most patients with advanced NSCLC don't receive guideline recommended treatment as their poor performance status makes them ineligible for platin-based treatment protocols. While tumour-specific loss of ATM in early-resected NSCLC is associated with poor survival, these patients derive increased benefit from adjuvant chemotherapy, including cisplatin. We have previously reported that ATM-deficient cell lines in MCL and gastric cancer show increased sensitivity to PARP inhibition, and recent studies have indicated cisplatin sensitivity arising from DNA damage repair deficiencies. Here we present preclinical data suggesting that lower doses of platin in combination with PARP inhibition may be an option in patients whose tumours exhibit ATM loss. Methods: We identified ATM-deficient NSCLC cell lines by protein expression and activation in response to ionizing radiation. Cells were treated with cisplatin and PARP inhibitor (olaparib) alone or in combinations to determine sensitivity by clonogenic survival assay. ATM was knocked out in an ATM-proficient cell line by Cas9-CRISPR gene editing, and cells were analyzed for the effect of cisplatin and olaparib on cell cycle progression. Results: ATM-deficient NSCLC cell lines were sensitive to both cisplatin and olaparib alone, and this effect was amplified when drugs were given in combination, even at lower doses of both. ATM signalling was activated in response to these drugs in ATM-proficient cells, however when ATM is knocked out the cells become more sensitive to either drug alone or in combination. Interestingly, apoptosis does not appear to increase in ATM-KO cells, but rather cells accumulate in G2 – particularly cells treated with olaparib. Conclusions: Our results suggest that ATM loss is sufficient to sensitize NSCLC cells to combinations of cisplatin and olaparib. PARP inhibition may arrest cells in G2, and while cisplatin does not appear to push cells into an apoptotic state, cell death might be triggered via another mechanism. This suggests that NSCLC patients with ATM loss in their tumour may benefit from lower doses of platin and PARP inhibitors, a combination that may allow increased uptake of palliative systemic treatment including the addition of immunotherapy. Legal entity responsible for the study: D. Gwyn Bebb. Funding: Glans-Look Lung Cancer Research. Disclosure: All authors have declared no conflicts of interest.
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
Authors: Gaurav Goyal, S. Vincent Rajkumar, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Angela Dispenzieri, Yi L. Hwa, Amie L. Fonder, Miriam A. Hobbs, Suzanne R. Hayman, Steven R. Zeldenrust, John A. Lust, Stephen J. Russell, Nelson Leung, Prashant Kapoor, Ronald S. Go, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Rahma Warsame, Robert A. Kyle, Shaji K. Kumar
Journal: Leukemia (2019)
Simultaneous unbiased and absolute quantification of a 500 protein panel in pancreatic cancer plasma using HRM mass spectrometry
Authors: H. Yu, J. Vowinckel, C. Escher, D. Heinzmann, N. Dupuis
Journal: Annals of Oncology (2019)

Background: Recent studies have demonstrated of utility of quantifying circulating proteins for early disease detection, prediction of therapeutic response, and treatment monitoring. Although the utility is clear, standardization of measurement methods for a large number of proteins from plasma remains challenging. Here, plasma proteins are detected using hyper-reaction monitoring (HRM) mass spectrometry in samples from normal and pancreatic cancer subjects. The data is acquired and analyzed simultaneously with unbiased label-free quantification of all proteins and absolute quantification of proteins from a > 500-protein panel constructed from stable-isotope standard (SIS) peptides. Methods: Plasma samples from subjects with Stage IV pancreatic cancer (PC, n = 6) and age matched healthy donors (n = 15) were prepared for mass spectrometry. Prior to analysis, a panel of SIS peptides, covering 582 plasma proteins, was spiked into each sample. All samples were acquired using nano-flow liquid chromatography with separation over a one-hour gradient coupled online to a Thermo Scientific Q Exactive HF mass spectrometer. Protein data was extracted using Spectronaut (Biognosys) and statistical analysis was conducted to identify disease associated biomarker candidates. Results: Analysis of the PQ500 panel enabled absolute quantification of 282 proteins across all samples. Univariate statistical testing identified 29 candidate proteins (27 up- and 2 down-regulated; q-value > 0.05 and fold change > 1.5). Key dysregulated proteins include CRP, SAA1, and C9. With unbiased, label-free quantification, 414 proteins were quantified, with 87 significantly regulated. In addition to the acute phase protein candidates identified in the PQ500 panel, 12 adhesion related protein candidates were identified (e.g. TLN1, MYH9, TPM4), 9 of which were decreased in PC. Notably, membrane associated ICAM1 and VCAM1, both potential therapeutic targets, were increased in PC. Conclusions: Combining PQ500 with unbiased label-free quantification enables comprehensive characterization of the plasma proteome, while at the same time providing absolute quantification for a large subset of well annotated, clinically relevant proteins. Legal entity responsible for the study: Biognosys AG, Schlieren, Switzerland. Funding: Biognosys AG, Schlieren, Switzerland. Disclosure: H. Yu, J. Vowinckel, C. Escher, D. Heinzmann, N. Dupuis: Employee: Biognosys AG.
Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
Authors: Tzu Hua Chen-Liang, Ana M Hurtado López, Laura Palomo, Teresa Bernal Del Castillo, Mar Tormo, Maria Lourdes Hermosin, María-José Jimenez, Navarro Blanca, Esperanza Such, Rafael Andres DEL Orbe Barreto, Nuria de Haro, Félix López Cadenas, Begoña Muiña, Raquel de Oña, Carmen Benet, Eduardo José Salido, Raul Teruel-Montoya, Fernando Ramos, Leonor Senent, Maria Díez-Campelo, Beatriz Arrizabalaga, Blanca Xicoy, Francisco José Ortuño, Francesc Solé, Guillermo Sanz, Andres Jerez
Journal: Blood (2018)
P122 Important role of dendritic cells in inflammatory arthritis
Authors: E Simader, A Puchner, V Saferding, E Goncalves-Alves, R Pfeifle, G Krönke, J Smolen, S Blüml
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> Important role of dendritic cells in inflammatory arthritis. <h3>Objectives</h3> Investigation of the role of CD11c<sup>+</sup> cells in joint inflammation and destruction. <h3>Methods</h3> We analyzed histological sections of K/BxN serum transfer arthritis as well as hTNFtg arthritis for the presence of CD11c<sup>+</sup> cells by immunohistochemistry. We used CD11c-diphteria toxin receptor (DTR) transgenic mice. K/BxN serum transfer arthritis was induced, and mice were given either DT or PBS or in wt and BARF3 deficient mice. In addition CD11c DTR mice were crossed into hTNFtg animals and also received either DT or PBS. The severity of arthritis was determined clinically and histologically. <h3>Results</h3> Both CD8<sup>+</sup>CD11c<sup>+</sup> and CD11b<sup>+</sup>CD11c<sup>+</sup>, can be found in synovial tissue in TNF driven arthritis. Upon depletion of CD11c<sup>+</sup> cells clinical signs of K/BxN serum transfer arthritis were significantly reduced. Histological analysis found reduced synovial inflammation after the depletion of CD11c<sup>+</sup> cells in K/BxN arthritis. In addition, local bone destruction and the number of osteoclasts was also significantly reduced. In addition to K/BxN arthritis, we found that also in TNF-driven arthritis depletion of CD11c<sup>+</sup> cells led to a striking reduction of synovial inflammation and a complete depletion of osteoclasts. <h3>Conclusions</h3> These data show that in addition to initiating an adaptive immune response, CD11c<sup>+</sup> dendritic cells, are also involved in innate effector mechanisms of inflammatory arthritis. Especially CD11b<sup>+</sup>CD11c<sup>+</sup> and monocyte derived inflammatory seem to play a role in inflammatory arthritis, suggesting that they could be an important therapeutic target. <h3>References</h3> Sarkar S, Fox DA. Dendritic cells in rheumatoid arthritis. <i>Front Biosci</i>. 2005;10:656–65. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. <i>Annu Rev Immunol</i> 31:563–604. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. <i>Nature</i> 1998;392(6673):245–52. <h3>Acknowledgements</h3> We would like to thank the Medical University of Vienna and especially Prof. Smolen for their support and all members of the University of Erlangen for their assistance. <h3>Disclosure of Interest</h3> None declared.
Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis
Authors: Dyana T. Saenz, Warren Fiskus, Taghi Manshouri, David N Saenz, Raffaella Soldi, Baohua Sun, Christopher Peter Mill, Agnieszka J Nowak, Steven M. Kornblau, Prithviraj Bose, Tapan M. Kadia, Courtney D. DiNardo, Lucia Masarova, Steve Horrigan, Joseph David Khoury, Sunil Sharma, Srdan Verstovsek, Kapil N. Bhalla
Journal: Blood (2018)
Evaluating New Rules on Transparency in Cancer Research and Drug Development
Authors: Thomas J. Hwang, Kerstin N. Vokinger, Rachel E. Sachs
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Authors: Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, Ziad Reguiai, Audrey Nosbaum, Audrey Lasek, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Nadia Raison-Peyron, Florence Tetart, Anne-Bénédicte Duval-Modeste, Laurent Misery, François Aubin, Anne Dompmartin, Cécile Morice, Catherine Droitcourt, Angèle Soria, Jean-Philippe Arnault, Juliette Delaunay, Emmanuel Mahé, Marie-Aleth Richard, Amélie Schoeffler, Jean-Philippe Lacour, Edouard Begon, Amélie Walter-Lepage, Anne-Sophie Dillies, Sandrine Rappelle-Duruy, Stéphane Barete, Nathalia Bellon, Nathalie Bénéton, Aude Valois, Sébastien Barbarot, Julien Sénéchal, Delphine Staumont-Sallé
Journal: Journal of the American Academy of Dermatology (2019)
Hemizygosity Enables a Mutational Transition Governing Fungal Virulence and Commensalism
Authors: Shen-Huan Liang, Matthew Z. Anderson, Matthew P. Hirakawa, Joshua M. Wang, Corey Frazer, Leenah M. Alaalm, Gregory J. Thomson, Iuliana V. Ene, Richard J. Bennett
Journal: Cell Host & Microbe (2019)